Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
Takeda Pharmaceutical said on September 14 that the US FDA has accepted its new drug application for zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, under priority review for the treatment of adults with moderate-to-severe plaque psoriasis. The filing…
To read the full story
Related Article
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
March 31, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials
December 19, 2025
BUSINESS
- LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
- Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
- Fujifilm AI Finds Potent New Inhibitors from Known Compound
October 6, 2026
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…